Macular degeneration patients treated with Lucentis saw their sight sharpen so radically that they could meet vision requirements for driving, researchers said. In the trial, about 40 percent of the 716 patients achieved vision of 20/40 or better after 12 months. Genentech has put the drug on the fast track for FDA approval. Story